Gout and Uric & Nucleic Acids
Online ISSN : 2435-0095
Current issue
Gout and Uric & Nucleic Acids
Showing 1-3 articles out of 3 articles from the selected issue
Cover
Introduction
Japanese Society of Gout and Uric & Nucleic Acids 2019 Guidelines for Management of Hyperuricemia and Gout 3rd edition
  • Ichiro Hisatome, Kimiyoshi Ichida, Ikuo Mineo, Akira Ohtahara, Kazuhid ...
    2020 Volume 44 Issue Supplement Pages sp-1-sp-40
    Published: March 30, 2020
    Released: March 30, 2020
    JOURNALS FREE ACCESS

    [Background] Accumulated evidences suggested that hyperuricemia may be risk for renal failures, cardiovascular disease and life-style related disease since the 2nd edition of the guideline for the management of hyperuricemia and gout published in 2010, while hyperuricemia is a definitive risk of gout and urolithiasis. Besides, the novel non-purine xanthine oxidoreductase inhibitors have been developed recently. However, it remains unclear whether pharmacological treatment for asymptomatic hyperuricemia may be recommended to protect from gout arthritis and renal and cardiovascular disease. [Objects] Japanese guideline for the management of hyperuricemia and gout the 3rd edition tend to be developed to prevent patients, from asymptomatic hyperuricemia and gout. [Methods] After setting the important clinical issues on hyperuricemia and gout, seven clinical questions accompanied by advantage and disadvantage outcomes have been selected. Using the systematic reviews on reports related to outcome of each clinical question, bias risk of each evidence has been estimated. Taken together with the estimation of body of evidence, patients’ opinions and medical economics, the recommendation for each clinical question has been determined. [Results] 1) NSAIDs, glucocorticoid and colchicine are equally recommended to be use for gout attack, 2) Lowering serum urate less than 6mg/dL is recommended to treat tophus, 3) Long term colchicine cover is recommended to treat gout patients after administration of urate lowering agents (ULAs) than short period colchicine cover, 4) ULAs are partially recommended to use for hyperuricemic patients with CKD in order to suppress the deterioration of renal function, 5) ULAs are not partially recommended to use for hyperuricemic patients with hypertension in order to improve the prognosis and suppress the cardiovascular events, 6) ULAs is not partially recommended to use for hyperuricemic patients with heart failure in order to improve the prognosis and to suppress the cardiovascular events, 7) Dietary education including restriction of alcohol abuse is recommended for management of hyperuricemia. The Japanese version was published on December in 2018. This guideline has been translated into English. [Conclusion] This guideline is expected to cover the decision making against the important clinical issues on hyperuricemia and gout.

    Download PDF (725K)
feedback
Top